How The Theravance Biopharma (TBPH) Story Is Reset Around Respiratory Assets And Cash [Yahoo! Finance]
Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
Last theravance biopharma, inc. - ordinary shares earnings: 2/24 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.theravance.com/investor-relations
Company Research
Source: Yahoo! Finance
The consensus fair value estimate for Theravance Biopharma has shifted from about US$26.71 to roughly US$15.83 per share, a cut of around 40% that resets expectations around what the stock might be worth. Analysts link this move to the CYPRESS outcome, with more bullish voices pointing to Yupelri, residual Trelegy rights, and cash as support, while more cautious views focus on the loss of ampreloxetine as an upside driver and lowered targets in the mid teens. As you read on, you will see how these moving parts shape the evolving Theravance story and what to watch next. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Theravance Biopharma. What Wall Street Has Been Saying ?? Bullish Takeaways BTIG keeps a Buy rating and highlights that, in its view, the current valuation can be supported by Yupelri, residual Trelegy rights, and the company's cash position after removing ampreloxetine from its model. H.C. Wai
Show less
Read more
Impact Snapshot
Event Time:
TBPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TBPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TBPH alerts
High impacting Theravance Biopharma, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
TBPH
News
- TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP InvestigatesPR Newswire
- Theravance Biopharma (TBPH) was downgraded by Oppenheimer Holdings, Inc. from "outperform" to "market perform".MarketBeat
- Theravance Biopharma (TBPH) had its "neutral" rating reaffirmed by B. Riley Financial, Inc.. They now have a $14.00 price target on the stock, down from $28.00.MarketBeat
- Theravance shuts down R&D efforts and cuts workforce by half after Phase III trial failure [Yahoo! Finance]Yahoo! Finance
- The Excruciating Failure That Could Cause Theravance, Down 27%, To Sell Itself [Yahoo! Finance]Yahoo! Finance
TBPH
Earnings
- 11/10/25 - Beat
TBPH
Sec Filings
- 3/3/26 - Form 8-K
- 2/24/26 - Form 4
- 2/24/26 - Form 4
- TBPH's page on the SEC website